A multiplexed approach to improve tumoral targeting and chemotherapeutic treatment

Active Research Project
Investigator(s): 
Linda Vahdat, M.D. Tracy Stokol, Ph.D. Benedict Law, Ph.D.
Last Updated: 
April 7, 2022

Drawbacks of nanoparticles are poor tissue extravasation, incomplete drug release, and off-targeted delivery to the reticuloendothelial system and organs. The Law lab developed a new nanofiber platform (NFP) displaying a unique dimension (0.5 x 5 x 100 nm) different from other nanoparticles. The NFP has an excellent tumor-targeting property. It can structurally transform into 10-times larger interfibril networks, serving as in situ depot promoting weeks-long local retention. Used as a drug carrier, the NFP possesses superior therapeutic efficacy concerning disease progression inhibition. It improves the survival of animals bearing triple-negative breast cancer tumors while exhibiting a favorable toxicity profile.

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065